CN101433584A - Pharmaceutical composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof - Google Patents
Pharmaceutical composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof Download PDFInfo
- Publication number
- CN101433584A CN101433584A CNA2008102044992A CN200810204499A CN101433584A CN 101433584 A CN101433584 A CN 101433584A CN A2008102044992 A CNA2008102044992 A CN A2008102044992A CN 200810204499 A CN200810204499 A CN 200810204499A CN 101433584 A CN101433584 A CN 101433584A
- Authority
- CN
- China
- Prior art keywords
- extract
- deficiency
- blood stasis
- heart disease
- coronary heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating qi deficiency and blood stasis type coronary heart disease and a preparation method thereof. The pharmaceutical composition selects astragalus root and salviae miltiorrhizae for combination and can be prepared into a preparation referred to any pharmacy; and the astragalus root and the salviae miltiorrhizae have specific use amounts: 1 to 50 portions of the astragalus root and 1 to 50 portions of the salviae miltiorrhizae. The pharmaceutical composition can also comprise the compositions of notoginseng and leech. The pharmaceutical composition has the functions of invigorating healthy qi, activating blood, removing stasis and the like and is used for treating coronary heart disease caused by qi deficiency and blood stasis. In addition, the invention also discloses the method for preparing the pharmaceutical composition.
Description
Technical field
The invention belongs to medicine field.The present invention relates to a kind of pharmaceutical composition for the treatment of coronary heart disease with qi deficiency and blood stasis; In addition, the invention still further relates to this preparation of drug combination method.
Background technology
In (one-tenth) medicine industry be traditional national industry and the international medicine, the particularly organic component of plant amedica, natural drug of China, also be current fast-developing rising industry, in China's medication economics, show unique characteristics.Modern production of traditional Chinese medicines research is the engineering of giving priority to of national next five-year plan, and lists the medium-term and long-term science and technology development planning of country and Shanghai City in.And modern traditional Chinese patent medicine product industrialization demonstration research improves and the enhanced Chinese medicine modernization of international competitiveness action plan with the main Chinese medicine industrial technology structural adjustment optimization of deeply being developed as of kind, industry size benefit just according to the market demand.On the basis of work on hand, utilization modern science and technology method and pharmacy means, according to the standard criterion of international endorsement, preferential development has independent intellectual property right, curative effect is clear and definite, toxic and side effects is little new drug, is the current hi-tech industrialization major fields of first developing of China.Therefore, select the Chinese medicine that market potential is huge, have international competitiveness, utilize modern science and technology to carry out secondary or three exploitations, promote the technological leapfrogging of Chinese medicine industry, and carry forward vigorously its industrialization process, become the Chinese medicine industry and be the modern Chinese medicine industry, drive the development of related industry, make it become the Chinese medicine " big kind " that has the meaning represented on the international market, realize that really Chinese medicine goes to the world, the Chinese medicine industry is just seemed most important.
Traditional Chinese medicine preparation is many to be technology with the decocting in water precipitate with ethanol, does not thoroughly break away from thick, big, black looks as yet, and the pharmaceutics of Chinese drugs development is in extremely hysteretic state, and novel form, new adjuvant and technical study are very weak; Efficiently, quick-acting, volume is little, single dose is little and store, carry, the fine quality of taking convenience is few, owing to above-mentioned many reasons, up to now, Chinese medicine does not also really enter international medical main flow market, is unfavorable for international competition and challenge.
Micropill is sphere or the class spherical preparation of a kind of diameter in 0.5-1.5mm scope.It is a kind of dosage decentralized dosage form, and a dosage often is made up of dispersive a plurality of unit, a common dosage by tens so that more than 100 piller form, compare with dosage form such as tablet that single dose is made up of a unit, have following characteristics:
1, can be extensively after pellet is taken, be evenly distributed in the gastrointestinal tract because dosage inclines and decentralizedly, medicine increases at gastrointestinal surface distributed area, drug bioavailability is improved and reduces or eliminates the zest medicine to the gastrointestinal zest.
2, the influence of the rotation unable to take food thing conveying rhythm and pace of moving things of micropill in gastrointestinal tract, diameter is less than the micropill of 2mm, even when sphincter of pylorus is closed, still can pass through pylorus, so micropill absorbs the influence that generally is not subjected to gastric emptying at gastrointestinal.If micropill non-biodegradable material coating, then can obtain favorable reproducibility, not rely on the zero-order release speed of pH.
3, micropill is further made slow release or controlled release preparation (realizing by packaging technique), its drug release behavior is a summation of forming each micropill drug release behavior of a dosage, error or the defective unlikely drug release behavior to whole preparation of indivedual micropills in preparation produces and has a strong impact on, and therefore is being better than slow releasing tablet aspect the repeatability of release rule, the concordance.
4, the micropill of several different rate of releasing drug can be made capsule on demand, both can make blood drug level reach therapeutic effect rapidly behind the clothes, can keep longer action time again, and plasma concentration curve is steady, and repeatability is arranged, and adverse reaction rate is low.
5, the compound capsule of being made up of different micropills can increase stability of drug, improves curative effect, reduces untoward reaction, and is convenient to control of quality when producing.
6, advantage is also arranged on technology, if any good mobility matter, easily filled capsules, content uniformity are little, are non-friable dosage form.
Along with the extensive use of micropill, various pill methods constantly produce, and have entered into full-automatic preparatory phase at present.We use the pill new technique, and the technology of preparing of research Chinese medicine pellet promotes the Chinese medicine preparation level.
The former pattern with decoction of the red arklemin micropill of stilbene prescription is in clinical practice, but because dosage form falls behind, seriously limited its development in the future.The study on the industrialization of the red arklemin micropill of stilbene is just to the improvement with real Modernization Significance of its dosage form of carrying out.
Summary of the invention
The objective of the invention is to propose a kind of pharmaceutical composition for the treatment of coronary heart disease with qi deficiency and blood stasis.
In order to reach above-mentioned purpose, the pharmaceutical composition of the treatment coronary heart disease with qi deficiency and blood stasis that the present invention proposes mainly selects the Radix Astragali, Radix Salviae Miltiorrhizae to make up, and makes said dosage form on any pharmaceutics.Concrete consumption is: Radix Astragali 1-50 part, Radix Salviae Miltiorrhizae 1-50 part is preferably: 10 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes.With these drug regimens, make each efficacy of drugs produce synergism, thereby can improve the various symptoms of the coronary heart disease that causes by blood stasis due to qi deficiency by tonification healthy energy, blood circulation promoting and blood stasis dispelling.Wherein, select for use the Radix Astragali to be because Radix Astragali nature and flavor are sweet, warm, return lung, spleen channel, have effects such as invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation, can be used for that the deficiency of vital energy is weak, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, the metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle are difficultly burst, burst for a long time do not hold back, blood deficiency dull yellowish colored skin, interior-heat are quenched one's thirst, the treatment of chronic nephritis proteinuria, diabetes and other diseases; Select for use Radix Salviae Miltiorrhizae to be because of Radix Salviae Miltiorrhizae nature and flavor hardship, to be slightly cold, GUIXIN, Liver Channel have stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the clear away heart-fire merit of relieving restlessness can be used for that menoxenia, amenorrhea dysmenorrhea, lump in the abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection are swollen and ache, the treatment of dysphoria and insomnia, hepatosplenomegaly, angina pectoris etc.More than two the flavor medicines complement each other, can reach the effect of good curing coronary heart disease with qi deficiency and blood stasis.
For reaching better therapeutic, pharmaceutical composition of the present invention also makes up with Radix Notoginseng, Hirudo, makes said dosage form on any pharmaceutics.Concrete consumption is: Radix Astragali 1-50 part, Radix Salviae Miltiorrhizae 1-50 part, Radix Notoginseng 1-50 part, Hirudo 1-50 part; Be preferably: 10 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes, 6 parts of Radix Notoginseng, 6 parts of Hirudos.This be because: the Radix Notoginseng sweet and slightly bitter taste, warm in nature, return liver, stomach warp, have the effect of dissipating blood stasis hemostasis, subduing swelling and relieving pain, cure mainly spitting of blood, spit blood, epistaxis is had blood in stool, metrorrhagia, traumatic hemorrhage, breast ventral spine pain, tumbling down swells and ache; The salty hardship of Hirudo nature and flavor, flat, have stimulate the menstrual flow, removing blood stasis with potent drugs detumescence effect, can be used for diseases such as menstruation apolipsis, lump in the abdomen stomachache, blood-retention, traumatic blood stasis are had a pain, carbuncle erysipelas.The two is all the product of invigorating blood circulation, and can assist Radix Salviae Miltiorrhizae jointly, to strengthen the effect of blood circulation promoting and blood stasis dispelling.
Aforementioned pharmaceutical compositions of the present invention can add various conventional adjuvant required when preparing different dosage form, as excipient, don't separate agent, lubricant, adhesive etc. and be prepared into any peroral dosage form commonly used, as soft capsule, hard capsule, pill, powder, tablet, oral liquid etc. with the method for Chinese medicinal of routine.
Pharmaceutical composition of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations, for example: these crude drug pulverizes can be mixed and made into powder and take after mixing it with water; Can be with these crude drug decoctings, make after concentrating.But bring into play drug effect better for each raw material that makes this pharmaceutical composition, preferably the Radix Astragali in the crude drug, Radix Salviae Miltiorrhizae, Radix Notoginseng have been carried out special extraction such as ethanol extraction, and the gained medicinal residues are further carried out water extract-alcohol precipitation, Hirudo has been carried out the extraction process by water extraction.
Another object of the present invention is to propose a kind of preparation of drug combination method for the treatment of coronary heart disease with qi deficiency and blood stasis.
For achieving the above object, the present invention takes following technical scheme:
(1) with the Radix Astragali, the Radix Salviae Miltiorrhizae of described weight proportion, adds the ethanol that 2-20 doubly measures 10%-80% concentration, reflux, extract, 2-4 time, each 1-3 hour, merge extractive liquid, filters, and reclaims ethanol, carry out drying at 40 ℃～100 ℃, or go up macroporous resin column, and use certain density ethanol elution, after eluent reclaims ethanol, carry out drying at 40 ℃～100 ℃, make dry extract 1;
(2) medicinal residues after the above extraction are added 2-20 times of water gaging and extract 1-3 time, each 1-3 hour, alcohol precipitation process is: medicinal liquid was concentrated into 0.5-2g crude drug/ml, and alcohol precipitation concentration is 30%-90%, leaves standstill 1-20 hour.The centrifuging and taking precipitation, dry back dry extract 2;
(3) merge dry extract 1 and dry extract 2, or add various adjuvants again, be prepared into said dosage form on any pharmaceutics with conventional method.
Pharmaceutical composition of the present invention also can comprise Radix Notoginseng, Hirudo component, and its corresponding preparation method comprises following processing step:
(1) with the Radix Astragali, Radix Salviae Miltiorrhizae, the Radix Notoginseng of described weight proportion, adds the ethanol that 2-20 doubly measures 10%-80% concentration, reflux, extract, 2-4 time, each 1-3 hour, merge extractive liquid, filters, and reclaims ethanol, carry out drying at 40 ℃～100 ℃, or go up macroporous resin column, and use certain density ethanol elution, after eluent reclaims ethanol, carry out drying at 40 ℃～100 ℃, make dry extract 1;
(2) medicinal residues after the above extraction are added 2-20 times of water gaging and extract 1-3 time, each 1-3 hour, alcohol precipitation process is: medicinal liquid was concentrated into 0.5-2g crude drug/ml, and alcohol precipitation concentration is 30%-90%, leaves standstill 1-20 hour.The centrifuging and taking precipitation, dry back dry extract 2;
(3) with the Hirudo coarse pulverization of described weight proportion, in 30 ℃～100 ℃ water, extract 1-4 time, concentrate at 30 ℃～80 ℃, and dry under 40 ℃～100 ℃, make dry extract 3;
(4) merge dry extract 1 and dry extract 2 and dry extract 3, pulverize, add conventional adjuvant, be prepared into said dosage form on any pharmaceutics with conventional method.
In the above-mentioned preparation method, when in the preferred steps (1) medicine being added alcohol reflux, add 10 times of amount 70% ethanol, reflux, extract, 3 times, each 1 hour; Step (2) medicinal liquid is concentrated into 1g crude drug/ml, and alcohol precipitation concentration is 80%, leaves standstill 4 hours; In the step (3), after the Hirudo coarse pulverization with described weight proportion, add 4 times of water gagings, extract each 1 hour 3 times at 60 ℃.Zoopery and human experiment experimental results show that: pharmaceutical composition of the present invention has functions such as tonification healthy energy, blood circulation promoting and blood stasis dispelling, the reinforcing and reducing combination, and blood circulation and removing stasis and just not hindering is used for the coronary disease disease that causes because of blood stasis due to qi deficiency.
The specific embodiment
Come further to set forth the preparation method of medicine of the present invention by the following examples.
Embodiment 1 (preparation of the micropill dosage form of pharmaceutical composition of the present invention)
A) take by weighing the Radix Astragali, each 10g of Radix Salviae Miltiorrhizae, the ethanol that adds 10 times of amount 70% concentration, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, filter, reclaiming ethanol to liquor strength is 0.125g crude drug/ml, last D101 type macroporous resin column, and with the ethanol elution of 70% concentration, eluent carries out drying at 60 ℃ after reclaiming ethanol, makes dry extract 1;
B) medicinal residues after the above extraction are added 10 times of water gagings and extract 2 times, each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, and alcohol precipitation concentration is 80%, leaves standstill 4 hours.The centrifuging and taking precipitation gets dry extract 2 after the drying;
C) take by weighing Radix Notoginseng 6g, the ethanol that adds 10 times of amount 70% concentration, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, filter, reclaiming ethanol to liquor strength is 0.125g crude drug/ml, last D101 type macroporous resin column, and with the ethanol elution of 70% concentration, eluent carries out drying at 60 ℃ after reclaiming ethanol, makes dry extract 3; Medicinal residues add 10 times of water gagings and extract 2 times, and each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, and alcohol precipitation concentration is 80%, leaves standstill 4 hours.The centrifuging and taking precipitation gets dry extract 4 after the drying;
D) merge dry extract 1 and dry extract 2 and dry extract 3 and dry extract 4, pulverize, add conventional adjuvant, make micropill according to the micropill processing technology.
Embodiment 2 (preparation of the micropill dosage form of pharmaceutical composition of the present invention)
A) take by weighing the Radix Astragali, each 10g of Radix Salviae Miltiorrhizae, Radix Notoginseng 6g, the ethanol that adds 10 times of amount 70% concentration, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, filter, reclaiming ethanol to liquor strength is 0.125g crude drug/ml, last D101 type macroporous resin column, and with the ethanol elution of 70% concentration, eluent carries out drying at 60 ℃ after reclaiming ethanol, makes dry extract 1;
B) medicinal residues after the above extraction are added 10 times of water gagings and extract 2 times, each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, and alcohol precipitation concentration is 80%, leaves standstill 4 hours.The centrifuging and taking precipitation, dry back dry extract 2;
C) take by weighing Hirudo 6g, coarse pulverization is extracted 3 times in 60 ℃ of water, and each 1 hour, concentrate at 60 ℃, and dry under 60 ℃, make dry extract 3;
D) merge dry extract 1 and dry extract 2 and dry extract 3, pulverize, add conventional adjuvant, make micropill according to the micropill processing technology.
Embodiment 3 (preparation of the hard capsule of pharmaceutical composition of the present invention)
A) take by weighing the Radix Astragali, each 10g of Radix Salviae Miltiorrhizae, Radix Notoginseng 6g, the ethanol that adds 10 times of amount 70% concentration, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, filter, reclaiming ethanol to liquor strength is 0.125g crude drug/ml, last D101 type macroporous resin column, and with the ethanol elution of 70% concentration, eluent carries out drying at 60 ℃ after reclaiming ethanol, makes dry extract 1;
B) medicinal residues after the above extraction are added 10 times of water gagings and extract 2 times, each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, and alcohol precipitation concentration is 80%, leaves standstill 4 hours.The centrifuging and taking precipitation, dry back dry extract 2;
C) take by weighing Hirudo 6g, coarse pulverization is extracted 3 times in 60 ℃ of water, and each 1 hour, concentrate at 60 ℃, and dry under 60 ℃, make dry extract 3;
D) merge dry extract 1 and dry extract 2 and dry extract 3, pulverize, add conventional adjuvant, make hard capsule according to the hard capsule processing technology.
Embodiment 4 (preparation of medicament composition granule agent of the present invention)
A) take by weighing the Radix Astragali, each 10g of Radix Salviae Miltiorrhizae, Radix Notoginseng 6g, the ethanol that adds 10 times of amount 70% concentration, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, filter, reclaiming ethanol to liquor strength is 0.125g crude drug/ml, last D101 type macroporous resin column, and with the ethanol elution of 70% concentration, eluent carries out drying at 60 ℃ after reclaiming ethanol, makes dry extract 1.；
B) medicinal residues after the above extraction are added 10 times of water gagings and extract 2 times, each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, and alcohol precipitation concentration is 80%, leaves standstill 4 hours.The centrifuging and taking precipitation, dry back dry extract 2;
C) take by weighing Hirudo 6g, coarse pulverization is extracted 3 times in 60 ℃ of water, and each 1 hour, concentrate at 60 ℃, and dry under 60 ℃, make dry extract 3;
D) merge dry extract 1 and dry extract 2 and dry extract 3, pulverize, or add conventional adjuvant, make granule according to the granule processing technology.
Embodiment 5 (preparation of pharmaceutical composition tablet of the present invention)
A) take by weighing the Radix Astragali, each 10g of Radix Salviae Miltiorrhizae, Radix Notoginseng 6g, the ethanol that adds 10 times of amount 70% concentration, reflux, extract, 3 times, each 1 hour, merge extractive liquid,, filter, reclaiming ethanol to liquor strength is 0.125g crude drug/ml, last D101 type macroporous resin column, and with the ethanol elution of 70% concentration, eluent carries out drying at 60 ℃ after reclaiming ethanol, makes dry extract 1;
B) medicinal residues after the above extraction are added 10 times of water gagings and extract 2 times, each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, and alcohol precipitation concentration is 80%, leaves standstill 4 hours.The centrifuging and taking precipitation, dry back dry extract 2;
C) take by weighing Hirudo 6g, coarse pulverization is extracted 3 times in 60 ℃ of water, and each 1 hour, concentrate at 60 ℃, and dry under 60 ℃, make dry extract 3;
D) merge dry extract 1 and dry extract 2 and dry extract 3, pulverize, add excipient and disintegrating agent, mixing is made granule, adds lubricant again, is pressed into tablet.
Claims (12)
1, a kind of pharmaceutical composition for the treatment of coronary heart disease with qi deficiency and blood stasis is characterized in that, it is the medicament that is prepared from by following materials based on weight: Radix Astragali 1-50 part, Radix Salviae Miltiorrhizae 1-50 part.
2, the pharmaceutical composition of treatment coronary heart disease with qi deficiency and blood stasis according to claim 1 is characterized in that, it is the medicament that mainly is prepared from by following materials based on weight: 10 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes.
3, the pharmaceutical composition of treatment coronary heart disease with qi deficiency and blood stasis according to claim 1 is characterized in that, it also comprises following materials based on weight: Radix Notoginseng 1-50 part, Hirudo 1-50 part.
4, the pharmaceutical composition of treatment coronary heart disease with qi deficiency and blood stasis according to claim 3 is characterized in that, it is the medicament that is prepared from by following materials based on weight: 10 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes, 6 parts of Radix Notoginseng, 6 parts of Hirudos.
5, according to the pharmaceutical composition of any one described treatment coronary heart disease with qi deficiency and blood stasis of claim 1-4, it is characterized in that, described medicament is a said dosage form on any pharmaceutics, is soft capsule or hard capsule or granule or pill or powder or tablet or oral liquid.
6, the pharmaceutical composition of treatment coronary heart disease with qi deficiency and blood stasis according to claim 5 is characterized in that, described dosage form is the micropill dosage form.
7, the preparation of drug combination method of a kind of claim 1 or 2 described treatment coronary heart disease with qi deficiency and blood stasis is characterized in that:
(1) with the Radix Astragali, the Radix Salviae Miltiorrhizae of described weight proportion, adds the ethanol that 2-20 doubly measures 10%-80% concentration, reflux, extract, 2-4 time, each 1-3 hour, merge extractive liquid, filters, and reclaims ethanol, carry out drying at 40 ℃～100 ℃, or go up macroporous resin column, and use certain density ethanol elution, after eluent reclaims ethanol, carry out drying at 40 ℃～100 ℃, make dry extract 1;
(2) medicinal residues after the above extraction are added 2-20 times of water gaging and extract 1-3 time, each 1-3 hour, alcohol precipitation process is: medicinal liquid was concentrated into 0.5-2g crude drug/ml, and alcohol precipitation concentration is 30%-90%, leaves standstill 1-20 hour.The centrifuging and taking precipitation, dry back dry extract 2;
(3) merge dry extract 1 and dry extract 2, or add various adjuvants again, be prepared into said dosage form on any pharmaceutics, be soft capsule or hard capsule or granule or pill or powder or tablet or oral liquid with conventional method.
8, the preparation of drug combination method of treatment coronary heart disease with qi deficiency and blood stasis as claimed in claim 7 is characterized in that, in the step (1), the Radix Astragali of described weight proportion, Radix Salviae Miltiorrhizae add 10 times of amount 70% ethanol, reflux, extract, 3 times, each 1 hour.
9, the preparation of drug combination method of treatment coronary heart disease with qi deficiency and blood stasis as claimed in claim 7 is characterized in that, in the step (2), extract 2 times with 10 times of water gagings, each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, alcohol precipitation concentration is 80%, leaves standstill 4 hours; In the step (3), after the Hirudo coarse pulverization with described weight proportion, add 4 times of water gagings, extract each 1 hour 3 times at 60 ℃.
10, the preparation of drug combination method of a kind of claim 3 or 4 described treatment coronary heart disease with qi deficiency and blood stasis is characterized in that, comprises the steps:
(1) with the Radix Astragali, Radix Salviae Miltiorrhizae, the Radix Notoginseng of described weight proportion, adds the ethanol that 2-20 doubly measures 10%-80% concentration, reflux, extract, 2-4 time, each 1-3 hour, merge extractive liquid, filters, and reclaims ethanol, carry out drying at 40 ℃～100 ℃, or go up macroporous resin column, and use certain density ethanol elution, after eluent reclaims ethanol, carry out drying at 40 ℃～100 ℃, make dry extract 1;
(2) medicinal residues after the above extraction are added 2-20 times of water gaging and extract 1-3 time, each 1-3 hour, alcohol precipitation process is: medicinal liquid was concentrated into 0.5-2g crude drug/ml, and alcohol precipitation concentration is 30%-90%, leaves standstill 1-20 hour.The centrifuging and taking precipitation, dry back dry extract 2;
(3) with the Hirudo coarse pulverization (crossing sieve No. 2) of described weight proportion, in 30 ℃～100 ℃ water, extract 1-4 time, concentrate at 30 ℃～80 ℃, and dry under 40 ℃～100 ℃, make dry extract 3;
(4) merge dry extract 1 and dry extract 2 and dry extract 3, pulverize, add conventional adjuvant, be prepared into said dosage form on any pharmaceutics, be soft capsule or hard capsule or granule or pill or powder or tablet or oral liquid with conventional method.
11, the preparation of drug combination method of the described treatment coronary heart disease with qi deficiency and blood stasis of claim 10 is characterized in that, the Radix Astragali of described weight proportion, Radix Salviae Miltiorrhizae, Radix Notoginseng add 10 times of amount 70% ethanol, reflux, extract, 3 times, each 1 hour.
12, the preparation of drug combination method of the described treatment coronary heart disease with qi deficiency and blood stasis of claim 10 is characterized in that, in the step (2), extract 2 times with 10 times of water gagings, each 1.5 hours, alcohol precipitation process was: medicinal liquid is concentrated into 1g crude drug/ml, alcohol precipitation concentration is 80%, leaves standstill 4 hours; In the step (3), after the Hirudo coarse pulverization with described weight proportion, add 4 times of water gagings, extract each 1 hour 3 times at 60 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008102044992A CN101433584A (en) | 2008-12-12 | 2008-12-12 | Pharmaceutical composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008102044992A CN101433584A (en) | 2008-12-12 | 2008-12-12 | Pharmaceutical composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101433584A true CN101433584A (en) | 2009-05-20 |
Family
ID=40708324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008102044992A Pending CN101433584A (en) | 2008-12-12 | 2008-12-12 | Pharmaceutical composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101433584A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897752A (en) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | Chinese medicinal composition and preparation method thereof |
| CN102068491A (en) * | 2010-12-24 | 2011-05-25 | 重庆时珍阁普生药业有限公司 | Medicinal composition for treating coronary heart disease and angina |
| CN102940669A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN103585339A (en) * | 2013-12-02 | 2014-02-19 | 刘学田 | Medicine for treating apoplectic hemiplegia |
| CN104288505A (en) * | 2014-09-10 | 2015-01-21 | 秦永双 | Traditional Chinese medicine preparation for treating qi deficiency and blood stasis type coronary heart disease and nursing method |
| CN108186877A (en) * | 2018-03-16 | 2018-06-22 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | For the Chinese medicine composition of syndrome of blood stasis due to qi deficiency myocardial infarction secondary prevention |
| CN115154500A (en) * | 2022-05-09 | 2022-10-11 | 云南赛森生物科技有限公司 | Traditional Chinese medicine composition capable of improving blood flow and resisting anoxia and preparation method |
-
2008
- 2008-12-12 CN CNA2008102044992A patent/CN101433584A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897752A (en) * | 2009-05-31 | 2010-12-01 | 金士力佳友(天津)有限公司 | Chinese medicinal composition and preparation method thereof |
| CN102068491A (en) * | 2010-12-24 | 2011-05-25 | 重庆时珍阁普生药业有限公司 | Medicinal composition for treating coronary heart disease and angina |
| CN102068491B (en) * | 2010-12-24 | 2012-06-20 | 重庆多普泰制药有限公司 | Medicinal composition for treating coronary heart disease and angina |
| CN102940669A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN102940669B (en) * | 2012-10-31 | 2014-05-14 | 成都医路康医学技术服务有限公司 | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN103585339A (en) * | 2013-12-02 | 2014-02-19 | 刘学田 | Medicine for treating apoplectic hemiplegia |
| CN104288505A (en) * | 2014-09-10 | 2015-01-21 | 秦永双 | Traditional Chinese medicine preparation for treating qi deficiency and blood stasis type coronary heart disease and nursing method |
| CN108186877A (en) * | 2018-03-16 | 2018-06-22 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | For the Chinese medicine composition of syndrome of blood stasis due to qi deficiency myocardial infarction secondary prevention |
| CN115154500A (en) * | 2022-05-09 | 2022-10-11 | 云南赛森生物科技有限公司 | Traditional Chinese medicine composition capable of improving blood flow and resisting anoxia and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101433584A (en) | Pharmaceutical composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof | |
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
| CN102362920A (en) | Chinese patent medicament for treating urticaria | |
| CN102145120B (en) | Traditional Chinese medicine composition suitable for treating Type II diabetes | |
| CN106692744A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
| CN100391444C (en) | Mammary aggregation elimination capsule and its preparation method | |
| CN105943701B (en) | Application of qi-tonifying and blood-activating medicine in preparation of insomnia medicine | |
| CN106421727A (en) | Traditional Chinese medicine composition for treating painful menstruation and preparation method and application thereof | |
| CN102526214A (en) | Traditional Chinese medicine preparation for treating angioneurotic headache and migraine | |
| CN102188580B (en) | Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof | |
| CN102343019A (en) | Chinese medicinal composition for treating amenorrhea and preparation method of preparation thereof | |
| CN104435641A (en) | Traditional Chinese medicine preparation for treating hyperthyroidism | |
| CN101085191A (en) | Pulse engendendering active component extraction and its preparation | |
| CN103356731A (en) | Xuesaitong tablet containing eucommia extract and panax notoginseng saponins and application thereof | |
| CN101385814A (en) | Medicine for treating the coronary heart disease and preparation method thereof | |
| CN116870076B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN102526415A (en) | Chinese medicinal composition for treating dysmenorrhea and preparation method of same | |
| CN101468144B (en) | Chinese medicine compound preparation for treating ventricular premature beat | |
| CN101716271B (en) | Chinese traditional medicine effective fraction composite used for curing coronary heart disease and preparation method thereof | |
| CN1316989C (en) | Capsule with dried human placemta and red sage root and its preparing process | |
| CN1724054A (en) | Medicinal prepn. for treating hypermenorrhea, and its prepn. method | |
| CN101104033A (en) | Traditional Chinese medicinal preparation for treating Parkinson's disease and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090520 |